Table 4.
Serological results of PCR-confirmed RSV cases by onset of illness compared to healthy controls.
| Variables | <6 Days RSV Illness n = 4 |
≥6 Days RSV Illness n = 4 |
RSV-infected n = 8 |
Healthy n = 90 |
RSV vs. Healthy | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Study case | Case 1 | Case 2 | Case 3 | Case 4 | Case 5 | Case 6 | Case 7 | Case 8 | |||
| Time Post-Onset [days] | 1 | 2 | 2 | 5 | 6 | 8 | 9 | 25 | |||
| Serum Collected [CDC week] | 51 | 46 | 45 | 48 | 44 | 14 | 46 | 1 | |||
| Recent Prior RSV Infection Profile by WB | No | No | No | No | No | No | Yes | Yes | 2 (25)* | 28 (31)* | P > 0.99* |
| PLA concentration [μg/mL] | 10.4 | 5.4 | 0.9 | 3.9 | 4.7 | 5.0 | 25.3 | 10.5 | 5.8 (2.6–13.0)† |
6.4 (5.5–7.4)† |
0.9 (0.4–2.0)‡ |
| RSV/A Neutralizing Antibodies [titer] | 128 | 512 | 64 | 181 | 256 | 181 | 724 | 512 | 245.1 (123.8–485.2)† | 173.5 (146.4–205.6)† | 1.4 (0.7–2.8)‡ |
| RSV/B Neutralizing Antibodies [titer] | 256 | 128 | 64 | 128 | 362 | 128 | 1024 | 724 | 234.8 (105.4–523.0)† | 171.7 (134.8–218.5)† | 1.4 (0.6–3.1)‡ |
PCR, real-time reverse transcription polymerase chain reaction.
RSV, respiratory syncytial virus.
WB, Western Blot.
PLA, palivizumab-like antibodies.
*
Data are reported as n (%) and p-value.
†
Data are reported as geometric mean (95% CI).
‡
Data are reported as geometric mean ratio of RSV-infected/Healthy (95% CI).